RT Journal Article
T1 Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?
A1 Díaz Navarro, Marta
A1 Cercenado Mansilla, Emilia
A1 Monte, Ariadna
A1 Visedo, Andrés
A1 Rodríguez, Carmen
A1 Pérez Granda, María Jesús
A1 Muñoz García, Patricia Carmen
A1 Guembe, María
AB BackgroundOritavancin (ORT) is a new single-dose lipoglycopeptide showing in vitro activity against staphylococci and vancomycin-resistant enterococci. However, there is no data regarding its potential use as a catheter lock solution are scarce. We constructed an in vitro model to analyze the efficacy and stability of an ORT lock solution against the biofilm of staphylococci and enterococci over 7 days at 37 °C.MethodsWe used Staphylococcus aureus, Staphylococcus epidermidis, and vancomycin-susceptible Enterococcus faecalis ATCC strains. We performed a metabolic activity assay using a 2-mg/ml solution of ORT over a 7-day incubation period at 37 °C. The solution was tested against 24-h biofilms of each strain at day 0 and 7. Metabolic activity was measured using the XTT assay, and median absorbance obtained at 490 nm in the spectrophotometer was compared between day 0 and day 7.ResultsThe percentage reduction in metabolic activity was 95.3 % between biofilms treated with ORT solution incubated for 7 days and biofilms treated with ORT solution before incubation.ConclusionOurs is a proof-of-concept study that shows ORT to be a potential treatment as a catheter lock solution for eradication of staphylococcal and E. faecalis biofilms. It is needed to further test ORT against more clinical strains and to compare its activity with other antimicrobials in a biofilm model.
PB Elsevier Ltd
SN 2405-8440
YR 2025
FD 2025-01-30
LK https://hdl.handle.net/20.500.14352/119223
UL https://hdl.handle.net/20.500.14352/119223
LA eng
NO Díaz-Navarro M, Cercenado E, Monte A, Visedo A, Rodríguez C, Pérez-Granda MJ, et al. Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci? Heliyon. 2025;11(2).
NO MG recibió apoyo del Programa Miguel Servet (ISCIIIMICINN, MSII18/00008) del Fondo de Investigación en Salud (FIS) del Instituto de Salud Carlos III (ISCIII), Madrid, España. MD-N fue apoyado por el FIS del ISCIII (FI22/00022). AV fue respaldado por la Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid y el Fondo Social Europeo (PEJD-2021-TL/BMD-21113). El estudio fue parcialmente financiado por las subvenciones de la Fundación Mutua Madrileña (FMM24/01), ISCIII (PI21/00344), IiSGM (2022-PI-II-COOPTR-01) y el Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa".
DS Docta Complutense
RD 20 mar 2026